

Remarks:


In response to the Restriction Requirement, applicant elects Group I, claims 1-9 for prosecution. Claims 10-34 have been canceled but applicant reserves the right to file divisional applications directed toward the subject matter of these claims. Additionally, the office action has issued a species election and applicant elects SEQ ID NO: 8 (cIBR), derived from ICAM-1 and reserves the right to include other species when a generic claim or linking claim is found allowable. Moreover, the office action indicated that a particular species of drug must be selected and applicant selects methotrexate in this respect.

Claims 35-42 have been added. Of these, claims 35-41 depends either directly or indirectly from claim 1. Claim 42 is independent. Specific support for these claims can be found at the following locations: claim 35 -- page 2, lines 21-24; claims 36 and 37 -- sequence listing, SEQ ID Nos. 2, 3, 4, 6, 7, 8, and 9; claim 38 -- page 2, line 34 to page 3, line 8; claim 39 -- peptidomimetics are well known to those of ordinary skill in the art; claim 40 -- page 2, lines 19-30; claim 41 -- page 2, line 34 to page 6, line 22; and claim 42 -- page 2, lines 19-28.

Any additional fee which is due in connection with this amendment should be applied against our Deposit Account No. 19-0522.

In view of the foregoing, a Notice of Allowance appears to be in order and such is courteously solicited.

Respectfully submitted,

By 
Tracey S. Truitt, Reg. No. 43,205
2405 Grand Boulevard, Suite 400
Kansas City, Missouri 64108
816/474-9050

ATTORNEYS FOR APPLICANT(S)